Takeda Net Income from 2010 to 2026
| TAK Stock | USD 18.76 0.00 0.00% |
Net Income | First Reported 2008-09-30 | Previous Quarter -11.8 B | Current Value 105.5 B | Quarterly Volatility 62.9 B |
Check Takeda Pharmaceutical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Takeda Pharmaceutical's main balance sheet or income statement drivers, such as Depreciation And Amortization of 919.4 B, Interest Expense of 165.8 B or Selling General Administrative of 805.7 B, as well as many indicators such as Price To Sales Ratio of 1.66, Dividend Yield of 0.0252 or PTB Ratio of 1.1. Takeda financial statements analysis is a perfect complement when working with Takeda Pharmaceutical Valuation or Volatility modules.
Takeda | Net Income | Build AI portfolio with Takeda Stock |
Historical Net Income data for Takeda Pharmaceutical serves as a key indicator of operational performance and financial stability. Tracking changes in this metric over time helps investors spot emerging trends before they become obvious, providing an edge in assessing whether Takeda Pharmaceutical Co represents a compelling investment opportunity.
Latest Takeda Pharmaceutical's Net Income Growth Pattern
Below is the plot of the Net Income of Takeda Pharmaceutical Co over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Takeda Pharmaceutical financial statement analysis. It represents the amount of money remaining after all of Takeda Pharmaceutical Co operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Takeda Pharmaceutical's Net Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Takeda Pharmaceutical's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 107.93 B | 10 Years Trend |
|
Net Income |
| Timeline |
Takeda Net Income Regression Statistics
| Arithmetic Mean | 135,223,647,964 | |
| Coefficient Of Variation | 82.25 | |
| Mean Deviation | 70,354,109,130 | |
| Median | 119,625,000,000 | |
| Standard Deviation | 111,221,749,210 | |
| Sample Variance | 12370277497.4T | |
| Range | 521.8B | |
| R-Value | 0.31 | |
| Mean Square Error | 11892013428.6T | |
| R-Squared | 0.1 | |
| Significance | 0.22 | |
| Slope | 6,921,166,478 | |
| Total Sum of Squares | 197924439959.1T |
Takeda Net Income History
Other Fundumenentals of Takeda Pharmaceutical
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Takeda Pharmaceutical Net Income component correlations
About Takeda Pharmaceutical Financial Statements
Takeda Pharmaceutical investors utilize fundamental indicators, such as Net Income, to predict how Takeda Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Income | 97.1 B | 92.3 B | |
| Net Income From Continuing Ops | 124.4 B | 163 B | |
| Net Income Applicable To Common Shares | 124.1 B | 173.5 B | |
| Net Income Per Share | 78.61 | 74.68 | |
| Net Income Per E B T | 0.55 | 0.59 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out the analysis of Takeda Pharmaceutical Correlation against competitors. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Takeda Pharmaceutical. If investors know Takeda will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Takeda Pharmaceutical assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 3.302 | Dividend Share 198 | Earnings Share 0.23 | Revenue Per Share | Quarterly Revenue Growth 0.042 |
The market value of Takeda Pharmaceutical is measured differently than its book value, which is the value of Takeda that is recorded on the company's balance sheet. Investors also form their own opinion of Takeda Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Takeda Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Takeda Pharmaceutical's market value can be influenced by many factors that don't directly affect Takeda Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Takeda Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Takeda Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Takeda Pharmaceutical's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.